October 19, 2016
The Ministry of Health, Labor and Welfare (MHLW) on October 18 ordered Ono Pharmaceutical to revise the label for its immune checkpoint inhibitor Opdivo (nivolumab) to add immune thrombocytopenic purpura (ITP) as a clinically significant adverse drug reaction (ADR). In...read more